List of Abraxane drug patents
Abraxane is owned by Abraxis Bioscience.
Abraxane contains Paclitaxel.
Abraxane has a total of 22 drug patents out of which 0 drug patents have expired.
Abraxane was authorised for market use on 07 January, 2005.
Abraxane is available in powder;intravenous dosage forms.
Abraxane can be used as treatment of lung cancer; treatment of breast cancer; treatment of pancreatic cancer, treatment of breast cancer; treatment of pancreatic cancer; treatment of lung cancer, treatment of lung cancer; treatment of pancreatic cancer, treatment of pancreatic cancer, treatment of pancreatic cancer; treatment of lung cancer; treatment of breast cancer, treatment of lung cancer.
The generics of Abraxane are possible to be released after 12 July, 2034.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8314156 | ABRAXIS BIOSCIENCE | Compositions and methods of delivery of pharmacological agents |
Dec, 2023
(8 months from now) | |
| US7923536 | ABRAXIS BIOSCIENCE | Compositions and methods of delivery of pharmacological agents |
Dec, 2023
(8 months from now) | |
| US8138229 | ABRAXIS BIOSCIENCE | Compositions and methods of delivery of pharmacological agents |
Dec, 2023
(8 months from now) | |
|
US7923536
(Pediatric) | ABRAXIS BIOSCIENCE | Compositions and methods of delivery of pharmacological agents |
Jun, 2024
(1 year, 2 months from now) | |
|
US8314156
(Pediatric) | ABRAXIS BIOSCIENCE | Compositions and methods of delivery of pharmacological agents |
Jun, 2024
(1 year, 2 months from now) | |
|
US8138229
(Pediatric) | ABRAXIS BIOSCIENCE | Compositions and methods of delivery of pharmacological agents |
Jun, 2024
(1 year, 2 months from now) | |
| US7820788 | ABRAXIS BIOSCIENCE | Compositions and methods of delivery of pharmacological agents |
Oct, 2024
(1 year, 7 months from now) | |
|
US7820788
(Pediatric) | ABRAXIS BIOSCIENCE | Compositions and methods of delivery of pharmacological agents |
Apr, 2025
(2 years from now) | |
| US9101543 | ABRAXIS BIOSCIENCE | Combinations and modes of administration of therapeutic agents and combination therapy |
Feb, 2026
(2 years from now) | |
| US7758891 | ABRAXIS BIOSCIENCE | Combinations and modes of administration of therapeutic agents and combination therapy |
Feb, 2026
(2 years from now) | |
| US8268348 | ABRAXIS BIOSCIENCE | Combinations and modes of administration of therapeutic agents and combination therapy |
Feb, 2026
(2 years from now) | |
| US8034375 | ABRAXIS BIOSCIENCE | Combinations and modes of administration of therapeutic agents and combination therapy |
Aug, 2026
(3 years from now) | |
|
US9101543
(Pediatric) | ABRAXIS BIOSCIENCE | Combinations and modes of administration of therapeutic agents and combination therapy |
Aug, 2026
(3 years from now) | |
|
US8268348
(Pediatric) | ABRAXIS BIOSCIENCE | Combinations and modes of administration of therapeutic agents and combination therapy |
Aug, 2026
(3 years from now) | |
|
US7758891
(Pediatric) | ABRAXIS BIOSCIENCE | Combinations and modes of administration of therapeutic agents and combination therapy |
Aug, 2026
(3 years from now) | |
|
US8034375
(Pediatric) | ABRAXIS BIOSCIENCE | Combinations and modes of administration of therapeutic agents and combination therapy |
Feb, 2027
(3 years from now) | |
| US9393318 | ABRAXIS BIOSCIENCE | Methods of treating cancer |
Mar, 2032
(8 years from now) | |
| US9597409 | ABRAXIS BIOSCIENCE | Methods of treating cancer |
Mar, 2032
(8 years from now) | |
|
US9393318
(Pediatric) | ABRAXIS BIOSCIENCE | Methods of treating cancer |
Sep, 2032
(9 years from now) | |
|
US9597409
(Pediatric) | ABRAXIS BIOSCIENCE | Methods of treating cancer |
Sep, 2032
(9 years from now) | |
| US9511046 | ABRAXIS BIOSCIENCE | Methods of treating pancreatic cancer |
Jan, 2034
(10 years from now) | |
|
US9511046
(Pediatric) | ABRAXIS BIOSCIENCE | Methods of treating pancreatic cancer |
Jul, 2034
(11 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Pediatric Exclusivity (PED) | Jun 6, 2023 |
Drugs and Companies using PACLITAXEL ingredient
Market Authorisation Date: 07 January, 2005
Treatment: Treatment of lung cancer; Treatment of pancreatic cancer; Treatment of breast cancer
Dosage: POWDER;INTRAVENOUS
ABRAXANE family patents
54
United States
29
Japan
24
Korea, Republic of
13
China
13
European Union
9
Russia
9
New Zealand
8
Portugal
8
Spain
8
Canada
8
Slovenia
8
Denmark
7
Poland
6
Mexico
6
Hong Kong
6
Cyprus
6
Hungary
6
Israel
6
Australia
5
Brazil
5
Lithuania
4
Taiwan, Province of China
4
South Africa
3
Singapore
1
Turkey
1
Croatia
1
Costa Rica
1
Norway
1
Austria
1
Luxembourg
1
RS
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic